SHARE - Symbicort and Health Economics in a Real Life Evaluation
Symbicort and Health Economics in a Real Life Evaluation - SHARE - A Randomised, Open-Label, Parallel-Group, Multicentre Study to Assess the Asthma-Related Health-Care Costs, in Ordinary Clinical Practice During 12 Months
2 other identifiers
interventional
1,970
1 country
108
Brief Summary
The purpose of this study is to compare health-related costs and asthma control in ordinary clinical practice during 12 months for Symbicort® given as a low maintenance dose plus as needed compared to a free combination of Pulmicortâ and Oxis® plus Bricanyl® as needed, and Symbicort fixed dosing plus Bricanyl as needed in asthmatic patients not adequately controlled on inhaled glucocorticosteroids alone.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3 asthma
Started Apr 2004
Longer than P75 for phase_3 asthma
108 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2004
CompletedFirst Submitted
Initial submission to the registry
November 25, 2005
CompletedFirst Posted
Study publicly available on registry
December 1, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2007
CompletedJanuary 24, 2011
January 1, 2011
November 25, 2005
January 21, 2011
Conditions
Outcome Measures
Primary Outcomes (1)
Asthma-related health-care utilization as measured by total amount of asthma medication purchased and number of contacts with health-care facilities
Secondary Outcomes (2)
Number of days patients or assistant persons are absent from work due to patient's asthma
Number of exacerbations and treatment failures
Interventions
Eligibility Criteria
You may qualify if:
- Signed informed consent,
- asthma,
- previously treated with glucocorticosteroids and B2-agonist
You may not qualify if:
- History of smoking, pregnancy, any significant disease or disorder which may put the patient at risk because of study participation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (108)
Research Site
Alingsås, Sweden
Research Site
Angered, Sweden
Research Site
Arlöv, Sweden
Research Site
Arvidsjaur, Sweden
Research Site
Arvika, Sweden
Research Site
Ängelholm, Sweden
Research Site
Åkersberga, Sweden
Research Site
Ånge, Sweden
Research Site
Årsta, Sweden
Research Site
Åstorp, Sweden
Research Site
Åtvidaberg, Sweden
Research Site
Bandhagen, Sweden
Research Site
Boden, Sweden
Research Site
Borensberg, Sweden
Research Site
Bro, Sweden
Research Site
Brunflo, Sweden
Research Site
Eskilstuna, Sweden
Research Site
Falun, Sweden
Research Site
Filipstad, Sweden
Research Site
Fränsta, Sweden
Research Site
Gagnef, Sweden
Research Site
Gärsnäs, Sweden
Research Site
Gothenburg, Sweden
Research Site
Grängesberg, Sweden
Research Site
Gullspång, Sweden
Research Site
Halmstad, Sweden
Research Site
Håby, Sweden
Research Site
Helsingborg, Sweden
Research Site
Hisingsbacka, Sweden
Research Site
Hofors, Sweden
Research Site
Höganäs, Sweden
Research Site
Höllviken, Sweden
Research Site
Huddinge, Sweden
Research Site
Iggesund, Sweden
Research Site
Jarfalla, Sweden
Research Site
Kalmar, Sweden
Research site
Karlskoga, Sweden
Research Site
Karlstad, Sweden
Research Site
Katrineholm, Sweden
Research Site
Kil, Sweden
Research Site
Kinna, Sweden
Research Site
Klippan, Sweden
Research Site
Kolmården, Sweden
Research Site
Kristinehamn, Sweden
Research Site
Kungälv, Sweden
Research Site
Kungsbacka, Sweden
Research Site
Kungsör, Sweden
Research Site
Landskrona, Sweden
Research Site
Laxå, Sweden
Research Site
Leksand, Sweden
Research Site
Lerum, Sweden
Research Site
Lidingö, Sweden
Research Site
Likenäs, Sweden
Research Site
Limhamn, Sweden
Research Site
Lindome, Sweden
Research Site
Linköping, Sweden
Research Site
Ljungskile, Sweden
Research Site
Ludvika, Sweden
Research Site
Luleå, Sweden
Research Site
Lund, Sweden
Research Site
Malmo, Sweden
Research Site
Mariefred, Sweden
Research Site
Mölndal, Sweden
Research site
Mölnlycke, Sweden
Research Site
Nacka, Sweden
Research Site
Norrköping, Sweden
Research Site
Norrtälje, Sweden
Research Site
Nyköping, Sweden
Research site
Osby, Sweden
Research site
Ödeshög, Sweden
Research Site
Örebro, Sweden
Research Site
Partille, Sweden
Research Site
Påarp, Sweden
Reseearch Site
Perstorp, Sweden
Research Site
Saltsjo-Bo, Sweden
Research Site
Sandviken, Sweden
Research Site
Sjöbo, Sweden
Research Site
Sjuntorp, Sweden
Research site
Sollentuna, Sweden
Research Site
Solna, Sweden
Research Site
Söderköping, Sweden
Research site
Stenstorp, Sweden
Research Site
Stenungsund, Sweden
Research Site
Stockholm, Sweden
Research Site
Storfors, Sweden
Research Site
Stugun, Sweden
Research Site
Sundbyberg, Sweden
Research Site
Sundsvall, Sweden
Research Site
Sunne, Sweden
Research Site
Täby, Sweden
Research Site
Trollhättan, Sweden
Research Site
Trosa, Sweden
Research Site
Tyresö, Sweden
Research Site
Uddevalla, Sweden
Research site
Ulricehamn, Sweden
Research Site
Umeå, Sweden
Research Site
Uppsala, Sweden
Research Site
Vallentuna, Sweden
Research Site
Varberg, Sweden
Research Site
Vännäs, Sweden
Research Site
Värnamo, Sweden
Research site
Väsby, Sweden
Research Site
Västerås, Sweden
Research Site
Västervik, Sweden
Research site
Västra Frölunda, Sweden
Research Site
Vellinge, Sweden
Research Site
Ystad, Sweden
Research Site
Ytterby, Sweden
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
AstraZeneca Symbicort Medical Science Director, MD
AstraZeneca
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
November 25, 2005
First Posted
December 1, 2005
Study Start
April 1, 2004
Study Completion
May 1, 2007
Last Updated
January 24, 2011
Record last verified: 2011-01